Comparative analysis of effectiveness of asthma control test-guided treatment versus usual care in patients with asthma from China - 11/05/21
Abstract |
Objective |
The present study compared the effectiveness of asthma control test (ACT)-guided treatment vs. usual care (UC) in patients with asthma from China.
Methods |
This prospective, phase IV, multicenter, cluster-randomized, open-label 24-week study was conducted in China; patients were randomized to either ACT-guided treatment or UC group. The patients recorded peak expiratory flow, symptoms, and medication in a diary card every day and completed ACT at every clinic visit. For the UC group, patients completed ACT after the physician's treatment decision.
Results |
In total, 83.6% patients (n = 443/530; ACT: n = 209, UC: n = 234) completed the study. A significantly higher proportion of patients (adjusted OR [95% CI]: 7.87 (1.29, 48.11; p = 0.027) responded to the treatment and had ACT total score ≥20 or demonstrated an improvement of >3 points in ACT total score in ≥1 post-baseline assessment in the ACT-guided treatment vs. UC group. A higher proportion of patients had an ACT total score ≥20 and an improvement of >3 points in ACT total score at Week 24 in the ACT-guided treatment vs. the UC group (adjusted OR (95% CI):2.28 (1.07, 4.85; p = 0.036). A significant difference (p = 0.005) in change from baseline in ACT total score was observed in ACT-guided treatment vs. UC group at Week 24. The mean annual exacerbation rate was similar in both the groups.
Conclusions |
ACT-guided treatment was more effective in achieving ACT total score ≥20 or showing an improvement of >3 points in the ACT total score and well tolerated compared with UC treatment in the 24-week treatment period.
Trial registration |
Clinical trials.gov Identifier: NCT02868281, clinicaltrials.gov/; GlaxoSmithKline study ID: 201097, www.gsk-studyregister.com/.
Le texte complet de cet article est disponible en PDF.Highlights |
• | More patients had improved ACT total score in ACT-guided vs. UC treatment group. |
• | FEV1 and ACT scores were higher in ACT-guided vs. UC treatment group. |
• | The mean annual exacerbation rate was similar in both the groups. |
• | Overall, ACT-guided was more effective than UC treatment in this 24-week study. |
Keywords : Adverse event, Asthma quality of life questionnaire, Exacerbations, Forced expiratory volume in 1 s, Inhaled corticosteroids, Long-acting β2 agonist, Prospective, Randomized, Serious adverse event
Plan
Vol 182
Article 106382- juin 2021 Retour au numéro
Article précédent
- Smoking and risk of COVID-19 hospitalization
- Daniel Puebla Neira, Abigail Watts, Justin Seashore, Efstathia Polychronopoulou, Yong-Fang Kuo, Gulshan Sharma
- Disputes over the production and dissemination of misinformation in the time of COVID-19
- Mario Cazzola, Vito de Novellis, Andrea Bianco, Paola Rogliani, Maria Gabriella Matera
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?